Lilly will acquire our mutant-selective PI3Kα inhibitor program, led by STX-478, a promising, next-generation treatment currently in Phase 1/2 trials for breast cancer and other advanced solid ...
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
MarketBeat on MSN11h
What Does the Future Hold for Eli Lilly?GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
To further bolster its pursuit of becoming a leading player in the oncology market, Lilly also recently announced that it is acquiring a clinical stage drug known as STX-478 from Scorpion ...
The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback